Double fast-track status awarded to Enzyvant’s rare disease drug by FDA
Swiss biopharma start-up Enzyvant has gained double fast track status from the FDA for its new rare disease candidate RVT-802. The investigational tissue-based therapy is for the treatment of complete DiGeorge Syndrome (cDGS), which represents a tiny subset of patients with the rare condition, DiGeorge Syndrome which is caused by a single gene defect.